Historical Valuation
Altimmune Inc (ALT) is now in the Fair zone, suggesting that its current forward PS ratio of 118142.51 is considered Fairly compared with the five-year average of -5.69. The fair price of Altimmune Inc (ALT) is between 0.51 to 4.64 according to relative valuation methord.
Relative Value
Fair Zone
0.51-4.64
Current Price：4.02
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Altimmune Inc (ALT) has a current Price-to-Book (P/B) ratio of 1.81. Compared to its 3-year average P/B ratio of 2.59 , the current P/B ratio is approximately -30.33% higher. Relative to its 5-year average P/B ratio of 2.46, the current P/B ratio is about -26.52% higher. Altimmune Inc (ALT) has a Forward Free Cash Flow (FCF) yield of approximately -18.12%. Compared to its 3-year average FCF yield of -22.84%, the current FCF yield is approximately -20.65% lower. Relative to its 5-year average FCF yield of -20.68% , the current FCF yield is about -12.37% lower.
P/B
Median3y
2.59
Median5y
2.46
FCF Yield
Median3y
-22.84
Median5y
-20.68
Competitors Valuation Multiple
AI Analysis for ALT
The average P/S ratio for ALT competitors is 23705.58, providing a benchmark for relative valuation. Altimmune Inc Corp (ALT.O) exhibits a P/S ratio of 118142.51, which is 398.37% above the industry average. Given its robust revenue growth of 0.00%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ALT
1Y
3Y
5Y
Market capitalization of ALT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ALT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ALT currently overvalued or undervalued?
Altimmune Inc (ALT) is now in the Fair zone, suggesting that its current forward PS ratio of 118142.51 is considered Fairly compared with the five-year average of -5.69. The fair price of Altimmune Inc (ALT) is between 0.51 to 4.64 according to relative valuation methord.
What is Altimmune Inc (ALT) fair value?
ALT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Altimmune Inc (ALT) is between 0.51 to 4.64 according to relative valuation methord.
How does ALT's valuation metrics compare to the industry average?
The average P/S ratio for ALT's competitors is 23705.58, providing a benchmark for relative valuation. Altimmune Inc Corp (ALT) exhibits a P/S ratio of 118142.51, which is 398.37% above the industry average. Given its robust revenue growth of 0.00%, this premium appears unsustainable.
What is the current P/B ratio for Altimmune Inc (ALT) as of Jan 10 2026?
As of Jan 10 2026, Altimmune Inc (ALT) has a P/B ratio of 1.81. This indicates that the market values ALT at 1.81 times its book value.
What is the current FCF Yield for Altimmune Inc (ALT) as of Jan 10 2026?
As of Jan 10 2026, Altimmune Inc (ALT) has a FCF Yield of -18.12%. This means that for every dollar of Altimmune Inc’s market capitalization, the company generates -18.12 cents in free cash flow.
What is the current Forward P/E ratio for Altimmune Inc (ALT) as of Jan 10 2026?
As of Jan 10 2026, Altimmune Inc (ALT) has a Forward P/E ratio of -3.14. This means the market is willing to pay $-3.14 for every dollar of Altimmune Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Altimmune Inc (ALT) as of Jan 10 2026?
As of Jan 10 2026, Altimmune Inc (ALT) has a Forward P/S ratio of 118142.51. This means the market is valuing ALT at $118142.51 for every dollar of expected revenue over the next 12 months.